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A major goal of current cancer research is to understand the functional consequences of mutations in recombinational DNA repair
genes. The introduction of artiﬁcial recombination substrates into living cells has evolved into a powerful tool to perform functional
analysis of DNA double strand break (DSB) repair. Here, we review the principles and practice of current plasmid assays with regard
to the two major DSB repair pathways, homologous recombination and nonhomologous end-joining. A spectrum of assay types is
availabletoassessrepairinawidevarietyofcelllines.However,severaltechnicalchallengesstillneedtobeovercome.Understanding
the alterations of DSB repair in cancers will ultimately provide a rational basis for drug design that may selectively sensitize tumor
cells to ionizing radiation and chemotherapy, thereby achieving therapeutic gain.
INTRODUCTION
The past few years have seen an explosive increase in the
understanding of both the molecular mechanisms and the
genetic determinants of recombinational DNA repair. Mu-
tations in genes controlling recombination lead not only to
defectiverepairofDNAdoublestrandbreaks(DSBs)andhy-
persensitivity to ionizing radiation (IR), but also to genomic
instability, developmental failure, and carcinogenesis [1, 2].
Particular excitement has been generated by the ﬁnding that
several cancer susceptibility syndromes result from muta-
tions in recombination-associated genes, including ataxia
telangiectasia (ATM), Nijmegen breakage syndrome (NBS1),
AT-Like disorder (Mre11), Fanconi Anemia (FANC genes),
Werner Syndrome (WRN), and certain familial breast can-
cers (BRCA1/2)[ 1, 2]. Sporadic mutations and polymor-
phisms in a variety of genes involved in recombination have
been found not only in normal tissues but also in malig-
nanttumors,includingBRCA1,RAD54,RAD52,andXRCC3
[3, 4]. However, it is largely unknown what the functional
signiﬁcanceofthesealterationsis.Thereistremendousinter-
estinabetterunderstandingoftheintricateproteinnetworks
in which these and other gene products cooperate. Undoubt-
edly, this knowledge will ultimately have signiﬁcant implica-
tions for cancer prevention and treatment.
The task of characterizing the in vivo repair phenotype
that results from any given spectrum of mutations in nor-
mal and malignant human cells is challenging. Several assays
are available, including the determination of cellular sensi-
tivity to genotoxic agents, cytological evaluation of repair-
associated processes and molecular analysis of DNA repair
products. Our laboratory has focused on the derivation and
application of DNA plasmid assays, which have evolved as
a powerful tool for the study of recombination in living
cells. Here, we review the principles and practice of current
plasmid assays with regard to the two major double strand
break repair pathways, homologous recombination (HR),
and nonhomologous end-joining (NHEJ). Due to space lim-
itations, we are only able to consider a small number of stud-
ies and data sets. For details on mechanisms and genetic de-
terminants of HR and NHEJ, the reader is referred to excel-
lent recent review articles [1, 4, 5]( including this issue of JBB,




The repair of a DSB by HR requires an undamaged tem-
plate molecule that contains a homologous DNA sequence.
Such a template can be provided by the sister chromatid,
the homologous chromosome, or an adjacent repetitive se-
quenceonthesamechromosome.SpeciﬁcallydesignedDNA
plasmid substrates typically model homology-directed DSB
repair by utilizing tandem repeats of a bacterial antibiotic
resistance gene. Commonly, the 18 base pair recognition
sequence for the rare-cutting I-SceI endonuclease is intro-
duced into one gene copy, thereby inactivating gene function
(for review [6] ) .T h es e c o n dc o p yi sm a d ei n a c t i v eb yo t h e r
means. The repair substrate is stably integrated into the cell’s
genome (Figure 1a). After the introduction of a break at the
I-SceI site, only a homology-mediated event can reconstitute
the gene and confer cellular resistance to a selection antibi-
otic in cell tissue culture. The design of the tandem repeat
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Figure 1. Illustration of the principles of measuring HR with plasmid assays. (a) Chromosomal DSB repair assay [14, 15] .Al i n e a r i z e dp l a s m i ds u b s t r a t e
containing mutated resistance or marker genes is transfected and stable chromosomal integrants are selected, for example, using a puromycin resistance gene.
Single-cell derived or pooled populations are ampliﬁed, and the integrated plasmid is characterized. Single or multiple copy integrants can be processed. The
I-SceI expression vector is transiently transfected and usually 48hours are allowed for the generation and homology-directed repair of I-SceI breaks within
the integrated substrate (black insertion). The HR frequency can be assessed by selecting for the recombined antibiotic resistance gene in a colony formation
assay (eg, GPT), or by assaying the marker gene product such as the green ﬂuorescent protein (GFP) via ﬂow cytometry (FACS). (b) Integration-associated
HR [18]. The linearized substrates p∆2a n dp ∆3, each carrying a mutated GPT gene copy (black boxes, gene deletions), are cotransfected. HR before and
during plasmid integration leads to the reconstitution of the resistance gene. Drug selection is used for isolation of stable recombinants in a colony formation
assay. (c) Homologous gene targeting [29]. Linearized p∆2puro is stably integrated using puromycin. Transient transfection of p∆3a l l o w sf o rH Rb e t w e e n
the chromosomal GPT gene copy and the extrachromosomal GPT.T h er e c o n s t i t u t e dGPT gene is selected for using colony formation. (d) Episomal HR with
replication [30]. An episomally replicating recombination substrate carrying mutated tandem repeats of a CAT reporter is transiently transfected together
with an I-SceI expression vector. Breaks are generated within one CAT copy (black insertion) and repaired via HR using a downstream homologous template.
After 48hours, episomal plasmids are extracted and tested for the functional CAT gene in a bacterial shuttle vector assay. (e) Extrachromosomal HR. The
mutatedrecombinationsubstrate(CAT orLuciferase gene)iscutpriortotransfection.HRreconstitutesthegenefunction,whichcanbemeasuredbyassaying
cell extracts in a luminometer or scintillation counter.88 Henning Willers et al 2:2 (2002)
assessment of genetically distinct subpathways of HR [7, 8].
Modiﬁcationsoftheplasmidsubstratehavepermittedstudy-
ing of interchromatid and even interchromosomal recombi-
nation [7, 9, 10]. Johnson and Jasin [11] recently reviewed
the use of the I-SceI system in mammalian cells.
ManylaboratorieshaveemployedtheI-SceIassay,mostly
in rodent cell lines [7, 8, 11, 12, 13, 14] .S e v e r a lg r o u p si n -
cluding our own have found up to 100-fold or more stimula-
tion of spontaneous recombination frequencies upon the ex-
pression of the I-SceI enzyme. These studies have established
thatchromosomalHRcanserveasasigniﬁcantalternativeto
NHEJ in mammalian cells. The I-SceI assay has provided in-
sight into the genetic determinants of HR. Reduced repair of
I-SceI breaks has been observed in the absence of functional
RAD51, RAD54, XRCC2, XRCC3, BRCA1, and BRCA2, and
these ﬁndings have correlated with increased cellular sensi-
tivity to IR [7, 8, 14, 15, 16, 17]. Thus, the repair of I-SceI
breaksisatleastpartiallycarriedoutbythesameproteinnet-
work that is involved in the repair of radiation-induced DNA
damage.
The ATM and p53 gene products, which are central pro-
teins in the DNA damage response pathway, have been re-
ported by us and others as being involved in the regulation
of HR [18, 19, 20, 21, 22]. The P53 gene has been observed
to suppress spontaneous HR by at least one order of magni-
tudeinawidevarietyofrodentandhumancelllines;andthis
could be a means by which p53 maintains genomic stability
[23]. Mutation of ATM, which is upstream of p53, led to in-
creased and error-prone HR (see below, section Plasmid as-
says containing extrachromosomal components) [18]. How-
ever, it has not yet been established whether and how ATM
and p53 inﬂuence the repair of the I-SceI breaks.
Several important technical caveats should be considered
when utilizing the I-SceI system (Figure 1a). Firstly, there is
usually substantial variation in the induction of recombina-
tion among several single-cell derived clones, implying that
the random integration site can have considerable inﬂuence
on recombination activity. One way of obtaining a represen-
tative sample of the cell population under study is to pool a
large number of colonies, which contain plasmids integrated
at various random sites in the genome. Secondly, in many
situations, extremely large amounts of I-SceI expression vec-
tor, that is, up to 100µg, need to be transfected for the eﬀect
to be seen. One possible explanation is that simple religa-
tion of I-SceI break ends is the dominating activity and that
therefore serial DSBs have to be induced to eventually trig-
ger an HR event. Thirdly, spontaneous HR frequencies can
be substantial and thus mask any DSB-induced recombina-
tion activity. However, it can be useful to isolate a clone that
exhibits a signiﬁcant spontaneous HR frequency and an at
least10-foldinductionaftertheexpressionofI-SceInuclease.
This would allow for parallel evaluation of spontaneous and
break-induced HR, which potentially have diﬀerent genetic
determinants. Lastly, it is important to stress that the exper-
iment typically spans two or more months involving several
rounds of transfection and colony formation. Therefore, it is
favorabletodevelopshorterassaysthatmakeuseofrecombi-
nation markers such as the green ﬂuorescent protein (GFP),
which will abrogate the need for one round of colony forma-
tion in diﬃcult to grow cell lines [14].
Celllineandbreaktypelimitations
From the data obtained with the I-SceI repair system,
arises the question whether this assay should be consid-
ered the “gold standard” to assess proﬁciency in homology-
mediated DSB repair. This assay provides an important
model system in cell lines that are characterized by rapid and
unlimited growth in tissue culture, by high transfection ef-
ﬁciencies (eg, > 10%) and suﬃcient colony forming abili-
ties (eg, > 5%). However, these requirements are only met
in a selected number of cell lines including immortal lines
such as Chinese hamster ovary cells or murine embryonic
stem (ES) cells. It is important to recognize that immortal
cell lines typically do not possess true functional wild-type
p53 status, including ES cells [24, 25, 26]. However, with the
loss of p53, the regulation of HR is expected to be relaxed
or disturbed [20, 24]. This likely aﬀects the functional anal-
ysis of other proteins involved in HR. In most cell lines with
wild-type p53 status, successful application of colony forma-
tion assays to measure HR is diﬃcult to accomplish because
of p53’s growth-inhibitory eﬀects. Exceptions may include
some tumor lines, for example, MCF-7 [20], and immortal
lymphoblastoid lines [27, 28]. Typical limitations to the uti-
lization of complex repair assays such as the I-SceI system are
displayed in Table 1.
Induction of chromosomal breaks by the I-SceI endonu-
clease generates a 4bp staggered cut that leaves free 3  hy-
droxy overhangs, which can be directly religated. As dis-
cussed,theproﬁciencytorepairthisbreaktypeviaHRcorre-
lates with the resistance to IR. However, IR creates far more
complex chromosomal break ends than endonucleases, and
it is therefore likely that several protein activities that partic-
ipate in the repair of radiation-induced chromosomal breaks
can be missed by an I-SceI type assay. The technical chal-
lenge, therefore, is to design assays that employ ends resem-
bling radiation type damage more closely, and this could
include cohesive but noncompatible cut sites, blunt ended
cuts, and dephosphorylated double-stranded ends. Conse-
quentially, such an approach would involve variably cut ex-
trachromosomal repair substrates, as no alternative to I-SceI
generated chromosomal breaks is yet available.
Plasmidassayscontainingextrachromosomal
components
The role of ATM for extrachromosomal and integration-
associated HR was investigated in our laboratory by Luo et
al (Figure 1b)[ 18]. This assay studies intermolecular HR be-
tween two plasmids, p∆2a n dp ∆3, which contain a 5  dele-
tion and a 3  deletion in the bacterial gpt gene, respectively.
T h eg e n ea r r a n g e m e n t sa r ei l l u s t r a t e di nFigure 2. The HR
and restoration of the gpt gene following the cotransfection
oftheplasmidsresultedinaresistancetoXHATMinacolony
formation assay. When the plasmids were cleaved at a dis-
tance from the gene, the HR frequency was 27-fold higher in
AT ﬁbroblasts than in normal human ﬁbroblasts. However,2:2 (2002) Recombinational DNA Repair 89
Table 1. Typical limitations to the use of I-SceI based plasmid assays for assessment of chromosomal DSB repair.
Limitations Cell type
Limited life span Primary MEFs
Primary human ﬁbroblasts
Poor tissue culture features (limited colony
formation, growth, and transfection
eﬃciency)
Primary MEFs (especially BRCA1/2 knock-outs)
Primary human ﬁbroblasts (especially NBS1)
Many tumor lines (eg, Capan-1)
Alteration of wild-type p53 function Immortalized MEFs
Mouse ES cells
SV-40 transformed human ﬁbroblasts
Most human tumor lines
Apoptosis proﬁciency Lymphoblastoid lines
MEF: mouse embryonic ﬁbroblasts.
p∆2
p∆3





Figure 2. Illustration of integration-associated HR (corresponding to
Figure 1b). Plasmid substrates p∆2a n dp ∆3 contain nonoverlapping 5  and
3  deletions, respectively. There is an area of shared homology of approx-
imately 400 bp. Experiments were carried out with cleavage at a distance
f r o mt h eg e n e ,t h a ti s ,E c o R I ,o rw i t h i nt h eg e n e ,t h a ti s ,K p n I .S e e[ 18]
for details. Homology-mediated recombination and gpt gene restoration
canoccurbefore,during,orshortlyafterchromosomalplasmidintegration.
Cellular resistance to XHATM is selected for after 48hours.
upon cleavage within the gpt gene, the frequencies diﬀered
only by 3-fold. One conclusion derived from these data was
that if the DNA termini are within or close to the recombina-
tion substrate, then the high frequency of extrachromosomal
recombination in AT cells is oﬀset by mis-repair of the re-
combining sequences.
Figure 1c illustrates an assay modiﬁcation, which utilizes
stablechromosomalintegrationofp∆2puroatarandomsite,
transient transfection of p∆3 and selection of gpt recom-
binants. Using this targeting principle, we could show that
BRCA2- and BRCA1-deﬁcient tumor cells are defective in
homology-mediatedrecombinationbetweenachromosomal
and an extrachromosomal substrate by one order of magni-
tude([29]andunpublisheddatafromourlab).Theresultsof
this assay are consistent with other reports showing reduced
homologousgenetargetingincellslackingBRCA2orBRCA1
[16, 17].
Purely extrachromosomal HR, that is, in the absence of
any integration step, can be assessed by employing episo-
malshuttlevectors(Figure 1d).OurdatasuggestthatBRCA2
maintains its stimulatory eﬀect on HR in cancer cells in this
somewhat less physiologic assay setting [29]. In contrast, ab-
sence of murine p53 has no impact on regulation of HR in
extrachromosomal plasmid substrates, in striking diﬀerence
to the suppression of chromosomal HR [30]. Figure 1e illus-
trates a rapid plasmid reactivation assay which employs CAT
orLuciferase reporters;however,itisunclearwhatthegenetic
determinants of this endpoint are.
Translational research in the postgenome era may ulti-
mately involve routine characterization of repair phenotypes
in primary ﬁbroblasts or tumor cells directly taken from
patients with known genetic proﬁles. Universally applicable
plasmid assays that partially or entirely contain extrachro-
mosomal components could provide a means to assess re-
combinational repair in cells that have limited growth char-
acteristics, and to assess the repair of various break types.
However, a signiﬁcant problem to be addressed involves the
physiological limits that extrachromosomal repair substrates
possess. For example, extrachromosomal DNA is easily sub-
jected to nucleolytic attack and is removed from chromatin
regulation processes. Therefore, it becomes critical to corre-
late the results of extrachromosomal assays with those of I-
SceI-based assays in deﬁned model systems and to charac-
terize the genetic determinants of extrachromosomal DSB
repair. At this stage of research, it appears that purely ex-
trachromosomal HR proceeds independently of p53, at least
in murine ﬁbroblasts [30]; thus necessitating the use of
integration-linked assays for analysis of p53-dependent HR
(Figures1b,1c,and2).Alternatively,assaysutilizingmutated
SV40 genomes can provide an important alternative to plas-
mid systems for assessment of chromatin-associated repair
mechanisms [19, 21, 23].90 Henning Willers et al 2:2 (2002)
NONHOMOLOGOUSEND-JOINING
Religationversusillegitimaterejoining
Nonhomologous end-joining of two double-stranded
DNA ends does not require an undamaged partner and does
not rely on extensive homologies between the recombin-
ing ends. Sometimes, NHEJ can utilize ﬂanking microho-
mologies spanning 2–6bp. Rejoining of the ends can oc-
cur after limited degradation at the termini. Furthermore,
in many cases end-joining involves sequence alterations by
small deletions, insertions, or inversions. Thus, the repair
process itself is error-prone. It is important to realize that re-
striction enzyme generated DSBs can be repaired by either
simple religation or illegitimate rejoining thereby destroying
the original sequence. It has been hypothesized that illegiti-
mate rejoining is more likely to occur with plasmid ends that
have been generated prior to cell transfection, possibly be-
cause the ends are subject to degradation once entering the
cell. In contrast, break induction in vivo such as by I-SceI
would be more prone to religation. However, our data sug-
gest that illegitimate rejoining of extrachromosomal I-SceI
b r e a k sc a no c c u ra tah i g hf r e q u e n c y ,t h o u g hi ti sd i ﬃcult
to assess the contribution of religation because a religated
break is indistinguishable to a recognition sequence that has
never been cut [30]. Lin et al [13] introduced a chromoso-
mal repair substrate into mouse L cells, which contained a
TK gene disrupted by an I-SceI site tandem repeat. Genera-
tion of DSBs led to the removal of the intervening sequence
and precise religation with reconstitution of one I-SceI site
in 33–65% of all NHEJ events. This is likely to be an over-
estimate, since NHEJ not resulting in restoration of the TK
open reading frame could not be selected for. In contrast to
cuts from endonucleases or restriction enzymes, radiation-
induced breaks can only be repaired by an illegitimate repair
process.
Thedilemmaofselection
In contrast to HR, it is diﬃcult to envision how NHEJ
can reconstitute the function of a reporter gene, which is
needed to allow the identiﬁcation of repair products within
a large cell population. When using a chromosomally inte-
grated reporter gene that is inactivated by the insertion of an
I-SceI recognition site, NHEJ would have to precisely remove
the insert in order to reconstitute gene function. In princi-
ple, this can be facilitated by placing regions of microhomol-
ogy upstream and downstream of the insert. However, such
an assay would only score a fraction of NHEJ events. Previ-
ously, investigators have grown up 100 or more unselected
colonies after induction of I-SceI breaks in an integrated HR
substrate (Figure 3a). Physical analysis using Southern blot-
ting and PCR on a clone by clone basis can provide a quan-
titative estimate of chromosomal NHEJ; however, this is an
extremely laborious process. The only available assay type
that uses drug selection for NHEJ events involves measuring
the frequency of random stable integration of a linearized
plasmid substrate (Figure 3b). Cells lacking components of
thenonhomologousrepairpathway,forexample,DNA-PKcs,
Ku, or XRCC4, display plasmid integration frequencies that
are reduced by 10-fold or more ([31] and unpublished data
fromourlab).However,factorsotherthanbreakend-joining
proﬁciency may inﬂuence plasmid integration, thus making
this assay subject to various biases.
As with HR, NHEJ has been historically studied using
extrachromosomal substrates. Several assay principles have
been employed. Figure 3c illustrates a variation that we have
used recently [32]. Circular plasmid molecules were lin-
earized between the viral promoter and the Luciferase re-
porter gene prior to transfection. In linearized plasmids, the
Luciferase gene cannot be expressed. Only after DSB rejoin-
ing with recircularization of the plasmid, the transcription
of the reporter gene can proceed. We showed that p53 could
e n h a n c eN H E Jo fD S B sw i t hc o h e s i v ee n d sb y2 -t o3 - f o l d
in rodent embryonic ﬁbroblasts, but only in the presence
of an additional exogenous DNA damage signal. The data
suggested that p53 was enhancing DSB rejoining speciﬁcally
by increasing the ability to reanneal short complementary
strands of single-stranded DNA. Using a similar assay prin-
ciple, Liang and Jasin [33] observed increased degradation of
DNA termini in Ku80-deﬁcient cells. However, in cells lack-
ing DNA-PKcs, plasmid rejoining proceeded normally. It is
therefore not clear as to which degree the pathways involved
in nonhomologous repair of radiation-induced DSBs and in
the rejoining of extrachromosomal plasmid ends overlap. A
more speciﬁc way to study the genetic determinants of NHEJ
is to utilize Rag1- and Rag2-initiated site-speciﬁc V(D)J re-
combination as a functional endpoint, which tests for the
functional presence of the DNA-PK complex, XRCC4, and
ligase IV (Figure 3d)[ 34]. This assay is analogous in design
to the HR shuttle vector assay.
In summary, as for HR, a variety of assays are available to
assess NHEJ in diﬃcult and easy to grow murine and human
cell lines. However, more study is needed to determine which
genetic pathways can be studied by any particular system.
TOWARD THERAPEUTIC GAIN
For genotoxic agents used in cancer treatment, a thera-
peutic gain is deﬁned by a better relation between the killing
of tumor and normal cells in a patient. With regard to IR, it
is important to realize that in most instances malignant cells
are neither more radiosensitive nor more radioresistant than
their normal counterparts. In some cases, mutations in cen-
tral recombination genes within the tumor appear to confer
a defect in DSB repair and consequential radiosensitivity, as
suggested for BRCA2 [29]. Such a mutation may either be
absent in the normal tissues, or be present as heterozygosity
but not conferring any repair phenotype, thus oﬀering ther-
apeutic gain upon treatment with DSB-inducing agents.
It is likely that recombinational repair in malignant cells
is generally altered compared to normal cells. For exam-
ple, the P53 gene is mutated or inactivated in the majority
of human tumors. Consequentially elevated HR may con-
tribute to the increased loss of heterozygosity and chromoso-
mal instability observed in many tumors, though the causal2:2 (2002) Recombinational DNA Repair 91
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Figure 3. Illustration of the principles of measuring NHEJ with plasmid assays. (a) Physical analysis of chromosomal NHEJ. Analogous to Figure 1a,I - S c e I
breaks are generated in an integrated HR substrate, but cells are plated with o u ts e l e c t i o na n t i b i o t i c .C o l o n i e sa r ea n a l y z e do nac l o n eb yc l o n eb a s i sfor an
NHEJ product using Southern blot and PCR. Alternatively, PCR of genomic DNA can be used for semiquantitative analysis of NHEJ [16]. (b) Random
plasmid integration [29, 31]. The transfection frequency of a linearized reporter plasmid as a measure of NHEJ is scored by selecting for the intact resistance
gene, for example, with puromycin. (c) Extrachromosomal rejoining assay [32]. A Luciferase expression plasmid is cleaved between the promoter and the
reporter gene prior to the transient transfection. In the cell, Luciferase c a no n l yb ee x p r e s s e df o l l o w i n gN H E Ja n dr e - c i r c u l a r i z a t i o no ft h ep l a s m i d .C e l l
extracts are assayed for Luciferase activity. (d) Episomal V(D)J recombination [34]. Analogous to Figure 1d, recombination signal sequences ﬂank a bacterial
transcription stop signal upstream of a CAT reporter. The plasmid is cotransfected with Rag1/Rag2 expression vectors. The cleavage of the signal sequences
followed by site-speciﬁc recombination removes the transcription stop signal, so that extracted plasmids can be assessed for CAT resistance in a bacterial
shuttle vector assay.
relationship has yet to be proven [2] .T h el o s so fc e l lc y c l e
control in tumor cells results in a larger fraction of cells be-
ing in the S and G2 phases of the cell cycle compared to
normal cells. Homology-directed DSB repair is thought to
be an important pathway in these phases. This is in con-
trast to the G1 phase, during which NHEJ is likely to domi-
nate because no sister chromatid is available to provide a ho-
mologous repair template. Therefore, HR may be commonly
elevated and deregulated in cancer cells. This could provide
a rationale basis for drug design targeting HR pathways and
thereby sensitizing tumors to IR. Therapeutic gain will result
especially in relation to non- or slowly proliferating normal
tissues, which are largely in the G0 or G1 phase and thus
repair mainly via NHEJ. A variety of functional assays in-
cluding plasmid systems and other means will be needed to
characterize DSB repair in cancer and normal cells and to92 Henning Willers et al 2:2 (2002)
allow predictions of the outcome of combined treatment ap-
proaches. However, as discussed here, several technical chal-
lenges with respect to functional analysis in vivo still need to
be overcome.
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